Topping estimates, Teva reports $5.1 billion Q3 revenue
A day after CEO steps down, company reports 2% increase in sales, with U.S. generics revenues up 6%.
A day after its CEO Jeremy Levin was ousted by the board, Teva Pharmaceuticals reported third-quarter earnings on Thursday that were unchanged from a year ago but ahead of analysts' estimates by one cent a share.
register with haaretz
Like us on Facebook and get articles directly in your news feed